NICE's severity modifiers misalign with public preferences in England & Wales, prioritising health gains at lower disease ...

To help inform the current debate on assisted dying, we have updated the findings of our 2019 palliative report with the ...

For the growing number of multi-indication medicines, challenges arise in assessing and paying for value across medicine indications with a uniform price (see our previous report and further ...

Bhaven N. Sampat is an economist by training, a Professor at the Department of Health Policy and Management at Columbia University, and a Research Associate at the National Bureau of Economic Research ...

This blog by Martina Garau (OHE) and Dr. Tina Wang (CIRS) provides a framework to navigate key aims, challenges and opportunities offered by recent initiatives and reflects on future prospects.

Ting (Tina) Wang is Associate Director, HTA Programme and Strategic Partnerships at the Centre for Innovation in Regulatory Science (CIRS). Tina leads CIRS’ work on HTA strategy and research as part ...

Stuart Carroll is a senior health economist and epidemiologist with over 18 years of experience, specialising in infectious diseases and vaccines, market access, health technology appraisal, public ...